Mining biomarkers for type 2 diabetic nephropathy based on urinary proteomics and metabolomics
Frontiers in Endocrinology · 22.06.2026 · 17
DOI: 10.3389/fendo.2026.1859999 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Endocrinology, online erschienen am 22.06.2026. Verfasst von Mindong Mi und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Laboratory, The First Affiliated Hospital of Ningbo University, Ningbo, China. Hauptthemen laut MEDLINE: Diabetic Nephropathies, Diabetes Mellitus, Type 2, Biomarkers, Proteomics. Die Arbeit nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ningbo Municipal Bureau of Science and Technology, Medical Science and Technology Project of Zhejiang Province.
Abstract (Originalsprache)
Background
To evaluate and identify urinary biomarkers for the early diagnosis and staging of diabetic kidney disease (DKD).
Methods
This study enrolled 200 participants, including healthy controls (NDM, n=50) and patients with type 2 diabetes. The diabetic patients were stratified by urinary albumin-to-creatinine ratio (ACR) into the following groups: normoalbuminuria (SDM, n=50), microalbuminuria (MADKD, n=50), and macroalbuminuria (ADKD, n=50). Utilizing an integrated multi-dimensional screening strategy, we systematically evaluated traditional urinary protein markers (urinary retinol−binding protein [URBP], urinary immunoglobulin G [UIgG], urinary transferrin [UTRF], urinary alpha−1−microglobulin [Uα1−MG], and urinary beta−2−microglobulin [Uβ2−MG]), 20 urinary amino acids, and urinary proteins identified via high-throughput mass spectrometry. Candidate proteins were validated by ELISA, and their diagnostic performance was assessed using ROC curve analysis, with ACR serving as the practical clinical reference.
Results
Among the traditional urinary protein markers, UTRF and UIgG demonstrated excellent diagnostic value, with areas under the curve (AUC) of 0.926 and 0.916, respectively. Among the amino acids, PRO showed the best diagnostic performance (AUC = 0.746). However, when all 20 urinary amino acids were combined into a diagnostic model, it exhibited outstanding diagnostic value (AUC = 0.928), outperforming individual amino acids and even traditional protein markers. From the top 50 proteins identified in the proteomic screening, serpin family A member 1 (SERPINA1) was determined to be a key protein. Subsequent ELISA validation and ROC analysis further confirmed that SERPINA1 possesses outstanding diagnostic capability (AUC = 0.964, 95% CI: 0.936–0.990), significantly outperforming other candidate proteins, namely osteoclast−associated Ig−like receptor (OSCAR), contactin 1 (CNTN1), and CD58 molecule (CD58).
Conclusions
Traditional proteins, especially UTRF/UIgG, hold diagnostic value. The 20-amino-acid combination (AUC = 0.928) outperformed them. This study first systematically identifies urinary SERPINA1 as a highly promising DKD biomarker, offering a novel target for early diagnosis and precise management.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Clinical Laboratory, The First Affiliated Hospital of Ningbo University, Ningbo, China.
- Third School of Clinical Medicine, Zhejiang Chinese Medical University, Hangzhou, China.
- Department of Nephrology, The First Affiliated Hospital of Ningbo University, Ningbo, China.
- Zhejiang Engineering Research Center of Innovative Technologies and Diagnostic and Therapeutic Equipment for Urinary System Diseases, Ningbo, China.
Förderung
- Ningbo Municipal Bureau of Science and Technology
- Medical Science and Technology Project of Zhejiang Province
Zitieren
APA
Mi, M., Xiong, T., Gong, J., Sun, W., Xu, T., Jiang, Q., Zhang, D., Zhang, J., Huang, J., & Liang, W. (2026). Mining biomarkers for type 2 diabetic nephropathy based on urinary proteomics and metabolomics. Frontiers in Endocrinology, 17. https://doi.org/10.3389/fendo.2026.1859999
Vancouver
Mi M, Xiong T, Gong J, Sun W, Xu T, Jiang Q, et al. Mining biomarkers for type 2 diabetic nephropathy based on urinary proteomics and metabolomics. Frontiers in Endocrinology. 2026;17. doi:10.3389/fendo.2026.1859999
BibTeX
@article{Mi2026,
author = {Mi, Mindong and Xiong, Tianhuan and Gong, Jiyong and Sun, Weijie and Xu, Tunguang and Jiang, Qifeng and Zhang, Danqing and Zhang, Junge and Huang, Jiancheng and Liang, Wei},
title = {Mining biomarkers for type 2 diabetic nephropathy based on urinary proteomics and metabolomics},
journal = {Frontiers in Endocrinology},
year = {2026},
volume = {17},
doi = {10.3389/fendo.2026.1859999}
}
EUVIMED